Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2026 (Transaction Date: April 9, 2026)
Context: The filing discloses a transaction in the Company's own shares as part of an existing share buyback programme. The purchases were executed by BNP Paribas SA under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
Share Repurchase Activity (April 9, 2026):
- Shares Purchased: 330,000 ordinary shares
- Lowest Price Paid: 2,124.00 GBp
- Highest Price Paid: 2,158.00 GBp
- Volume-Weighted Average Price (VWAP): 2,139.38 GBp
- Total Shares Purchased: 17,896,521 ordinary shares
- Treasury Shares Held: 257,787,615
- Ordinary Shares in Issue (excluding Treasury): 4,058,396,834
- Total Voting Rights: 4,058,396,834
- Treasury Voting Rights Percentage: 6.35%
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the reduction of outstanding shares and the increase in treasury holdings. Following the April 9 transaction, the Company's treasury holding increased to approximately 257.8 million shares, representing 6.35% of the total voting rights. This activity is consistent with the ongoing buyback programme initiated in February 2026.
Guidance, Outlook, and Risks
Management Commentary: The Company confirms the purchase forms part of its existing buyback programme. No specific operational guidance or financial outlook is provided in this filing.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025.
Investor Verification Checklist
- Verify the total number of shares in issue (4,058,396,834) for accurate calculation of ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the 6.35% voting rights held in treasury to assess potential dilution or concentration effects.
- Review the non-discretionary agreement terms announced on February 17, 2026, to understand the remaining capacity of the buyback programme.
- Check the Annual Report on Form 20-F for 2025 for detailed risk factors referenced in the cautionary statement.